Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell(Instituto Oncológico Dr. Rosell), Rolf A. Stahel(International Breast Cancer Study Group), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), José Gómez‐Codina(Leitat Technological Center), Barbara Ruepp(The Coordinating Center), Ramón Palmero(Institut Català d'Oncologia), Alessandra Curioni‐Fontecedro(University of Fribourg), Emer O. Hanrahan(Cancer Trials Ireland), Martin Früh(University of Bern), Sanjay Popat(Royal Marsden NHS Foundation Trust), David S. Shames(Gene Therapy Laboratory), Roswitha Kammler(International Breast Cancer Study Group), Carlos Camps(Universitat de València), Adolfo Favaretto(Istituto Oncologico Veneto), Miguel Ángel Molina‐Vila(Hospital Universitario Dexeus), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Solange Peters(University Hospital of Lausanne), Javier Puente(Hospital Clínico San Carlos), Daniel Rauch(Washington University in St. Louis), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Marie Kassapian(Frontier Science Foundation-Hellas), Patrizia Froesch(Institute of Oncology Research), Niki Karachaliou(Institut Català d'Oncologia), Αthanasios Kotsakis(University Hospital of Heraklion), Urania Dafni(Frontier Science Foundation-Hellas), Noemı́ Reguart(Hospital Clínic de Barcelona), Fabrice Barlési(Hôpital Nord), Sinéad Cuffe(Cancer Trials Ireland), Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Enriqueta Felip(Institut Català d'Ornitologia), Enric Carcereny(Institut Català d'Ornitologia), Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), Michael Thomas, Rut Porta(Catalan Institute for Water Research), Rachel Tam, Linda Coate(University Health Network), Santiago Ponce Aix(Research Institute Hospital 12 de Octubre), Manuela Rabaglio(University Hospital of Bern), Miklos Pless(Ontario Institute for Cancer Research)
Cited by 184
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k